The association of sleep quality and night sleep duration with coronary heart disease in a large-scale rural population

2021 ◽  
Vol 87 ◽  
pp. 233-240
Author(s):  
Bin Zhang ◽  
Yan Wang ◽  
Xiaotian Liu ◽  
Zhihan Zhai ◽  
Jiaqi Sun ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Sleep Quality ◽  
Sleep Duration ◽  
Rural Population ◽  
Large Scale ◽  
Night Sleep

scholarly journals Sleep duration, sleep quality and coronary heart disease mortality

2016 ◽  
Vol 223 ◽  
pp. 534-535 ◽  
Author(s):  
Linn B. Strand ◽  
Min Kuang Tsai ◽  
David Gunnell ◽  
Imre Janszky ◽  
Chi Pang Wen ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Sleep Quality ◽  
Sleep Duration ◽  
Coronary Heart Disease Mortality ◽  
Disease Mortality

scholarly journals Sleep Quality, Sleep Duration, and the Risk of Coronary Heart Disease: A Prospective Cohort Study With 60,586 Adults

2018 ◽  
Vol 14 (01) ◽  
pp. 109-117 ◽  
Author(s):  
Xiang Qian Lao ◽  
Xudong Liu ◽  
Han-Bing Deng ◽  
Ta-Chien Chan ◽  
Kin Fai Ho ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Cohort Study ◽  
Heart Disease ◽  
Sleep Quality ◽  
Sleep Duration ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Quality Sleep

scholarly journals Correlation between Occupational Stress and Coronary Heart Disease in Northwestern China: A Case Study of Xinjiang

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Wu-Hong Lu ◽  
Wen-Qian Zhang ◽  
Fei Sun ◽  
Ya-Ting Gao ◽  
Yun-Juan Zhao ◽  
...  
Keyword(s):  
Physical Activity ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Sleep Quality ◽  
Occupational Stress ◽  
Sleep Duration ◽  
Stress Level ◽  
Western China ◽  
The Difference ◽  
Uygur Population

Objective. To study the correlation between occupational stress and coronary heart disease in western China. Method. A case-control design was used. From June 2016 to May 2017, 310 patients with coronary heart disease (CHD) confirmed by coronary angiography (CAG) at the Heart Center of the First Affiliated Hospital of Xinjiang Medical University were recruited by cluster sampling, along with 536 healthy controls. The questionnaire was developed based on a Job Content Questionnaire (JCQ). An epidemiological survey was conducted to collect clinical data. Chi-squared test, analysis of variance, and binary logistic regression analysis were adopted. Results. (1) In the Han population, there were statistically significant differences in the composition of smoking, diets, sleep duration, sleep quality, and physical activity between two groups (all P < 0.05 ). In the Uygur population, statistically significant differences in the composition of smoking, drinking, diets, sleep quality, and physical activity were found between two groups (all P < 0.05 ). (2) Differences in sleep duration and physical activity between the Han and Uygur case groups were statistically significant ( P < 0.05 ). (3) Differences in Gensini scores between the Han and Uygur case groups were statistically significant ( P < 0.05 ). Differences in coronary artery lesions between the Han and Uygur case groups were statistically significant ( P < 0.05 ). (4) In the Uygur population, the difference between the occupational stress level and CHD were statistically significant ( P < 0.05 ). (5) The differences between the number of different pathological changes and the level of occupational stress in the Han and Uygur case groups were not statistically significant ( P > 0.05 ). In the Han and Uygur case groups, the difference between the occupational stress level and Gensini high-level group were statistically significant ( P < 0.05 ). (6) After adjustment for age and sex, significant increased risk effects for Han patients with CHD were found to be associated with sleep quality ( OR = 1.88 ; 95% CI: 1.047-1.782; P < 0.05 ). Uygur patients with CHD was significantly associated with smoking ( OR = 3.094 ; 95% CI: 1.025-1.103; P < 0.05 ) and occupation stress ( OR = 1.523 ; 95% CI: 1.757-3.062; P < 0.05 ). Conclusion. Occupational stress is correlated with CHD for the Uygur population.

scholarly journals Large-scale phenome-wide association study of PCSK9 loss-of-function variants demonstrates protection against ischemic stroke

2017 ◽  
Author(s):  
Abhiram S. Rao ◽  
Daniel Lindholm ◽  
Manuel A. Rivas ◽  
Joshua W. Knowles ◽  
Stephen B. Montgomery ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Ischemic Stroke ◽  
Protective Effect ◽  
Large Scale ◽  
Artery Bypass ◽  
Bypass Graft ◽  
Genetic Associations ◽  
Loss Of Function

AbstractPCSK9 inhibitors are a potent new therapy for hypercholesterolemia and have been shown to decrease risk of coronary heart disease. Although short-term clinical trial results have not demonstrated major adverse effects, long-term data will not be available for some time. Genetic studies in large well-phenotyped biobanks offer a unique opportunity to predict drug effects and provide context for the evaluation of future clinical trial outcomes. We tested association of the PCSK9 loss-of-function variant rsll591147 (R46L) in a hypothesis-driven 11 phenotype set and a hypothesis-generating 278 phenotype set in 337,536 individuals of British ancestry in the United Kingdom Biobank (UKB), with independent discovery (n = 225K) and replication (n = 112K). In addition to the known association with lipid levels (OR 0.63) and coronary heart disease (OR 0.73), the T allele of rs11591147 showed a protective effect on ischemic stroke (OR 0.61, p = 0.002) but not hemorrhagic stroke in the hypothesis-driven screen. We did not observe an association with type 2 diabetes, cataracts, heart failure, atrial fibrillation, and cognitive dysfunction. In the phenome-wide screen, the variant was associated with a reduction in metabolic disorders, ischemic heart disease, coronary artery bypass graft operations, percutaneous coronary interventions and history of angina. A single variant analysis of UKB data using TreeWAS, a Bayesian analysis framework to study genetic associations leveraging phenotype correlations, also showed evidence of association with cerebral infarction and vascular occlusion. This result represents the first genetic evidence in a large cohort for the protective effect of PCSK9 inhibition on ischemic stroke, and corroborates exploratory evidence from clinical trials. PCSK9 inhibition was not associated with variables other than those related to low density lipoprotein cholesterol and atherosclerosis, suggesting that other effects are either small or absent.

Drug Treatment in the Prevention of Coronary Artery Disease

1979 ◽  
Author(s):  
J.R.A. Mitchell
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Heart Disease ◽  
Clinical Trials ◽  
Heart Disease ◽  
Major Part ◽  
Large Scale ◽  
End Points ◽  
Pump Failure ◽  
Artery Disease

The disappointing performance of anticoagulants in the prophylaxis of coronary heart disease led to the realisation that components other than fibrin play a major part in the structure of arterial thrombi. Attention has therefore been focussed on the possible role of agents which modify platelet behaviour. Novel agents which alter thromboxane synthesis will not be available for large-scale clinical trials for some years, so the present trials are assessing the value of platelet-modifying agents which are already in use for other purposes. The implications of the Antura-Reinfarction study and the role of aspirin and persantin will be discussed.Attention will also be drawn to the importance of using valid end-points to assess potential anti-thrombotic regimes in coronary disease. The differential implications of using infarction, sudden death, pump failure, dysrhythmias and re-infarction as end-points in trials will be described.

Sign in / Sign up

Export Citation Format

Share Document